Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qinghe Liang

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Viruses|November 25, 2023
Immune-Cell-Based Therapy for COVID-19: Current StatusYiyuan Wang, Qinghe Liang, Fengsheng Chen, et al.
Pharmacological Research|August 15, 2025
Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseasesBinhua Zou, Jiehuang Zheng, Weili He, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|October 14, 2023
Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathwayRuopeng Li, Qinghe Liang, Qin Yang, et al.
Biochemical Pharmacology|March 7, 2026
A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapyZiye Chen, Ruopeng Li, Fengsheng Chen, et al.
Biochemical Pharmacology|February 15, 2026
An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysisQinghe Liang, Wenqi Dai, Jiehuang Zheng, et al.
International Immunopharmacology|June 3, 2026
Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2Ziye Chen, Yuecheng Wang, Hongyan Guo, et al.
Pharmacological Research|October 20, 2022
IKKβ increases neuropilin-2 and promotes the inhibitory function of CD9<sup>+</sup> Bregs to control allergic diseasesYiyuan Wang, Wende Deng, Juan Liu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 5, 2026
Hexahydrocurcumin inhibits osteoclastogenesis and bone destruction in osteoporosis by targeting c-SrcLihong Li, Wenqi Dai, Zhuwei Zhong, et al.
Journal of Advanced Research|March 31, 2024
Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destructionJiehuang Zheng, Weili He, Yan Chen, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 10, 2024
Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitorYan Chen, Jiehuang Zheng, Lixia Mo, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Viruses|November 25, 2023
Immune-Cell-Based Therapy for COVID-19: Current StatusYiyuan Wang, Qinghe Liang, Fengsheng Chen, et al.
Pharmacological Research|August 15, 2025
Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseasesBinhua Zou, Jiehuang Zheng, Weili He, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|October 14, 2023
Hexahydrocurcumin from Zingiberis rhizoma attenuates lipopolysaccharide-induced acute pneumonia through JAK1/STAT3 signaling pathwayRuopeng Li, Qinghe Liang, Qin Yang, et al.
Biochemical Pharmacology|March 7, 2026
A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapyZiye Chen, Ruopeng Li, Fengsheng Chen, et al.
Biochemical Pharmacology|February 15, 2026
An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysisQinghe Liang, Wenqi Dai, Jiehuang Zheng, et al.
International Immunopharmacology|June 3, 2026
Kirenol, a diterpene active component from Siegesbeckia orientalis, alleviates atopic dermatitis by suppressing TYK2Ziye Chen, Yuecheng Wang, Hongyan Guo, et al.
Pharmacological Research|October 20, 2022
IKKβ increases neuropilin-2 and promotes the inhibitory function of CD9<sup>+</sup> Bregs to control allergic diseasesYiyuan Wang, Wende Deng, Juan Liu, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 5, 2026
Hexahydrocurcumin inhibits osteoclastogenesis and bone destruction in osteoporosis by targeting c-SrcLihong Li, Wenqi Dai, Zhuwei Zhong, et al.
Journal of Advanced Research|March 31, 2024
Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destructionJiehuang Zheng, Weili He, Yan Chen, et al.
Phytomedicine : International Journal of Phytotherapy and Phytopharmacology|May 10, 2024
Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitorYan Chen, Jiehuang Zheng, Lixia Mo, et al.
Pageof 2